JP2012517017A - Ｊｃポリオーマウイルスの検出のための方法 - Google Patents
Ｊｃポリオーマウイルスの検出のための方法 Download PDFInfo
- Publication number
- JP2012517017A JP2012517017A JP2011549163A JP2011549163A JP2012517017A JP 2012517017 A JP2012517017 A JP 2012517017A JP 2011549163 A JP2011549163 A JP 2011549163A JP 2011549163 A JP2011549163 A JP 2011549163A JP 2012517017 A JP2012517017 A JP 2012517017A
- Authority
- JP
- Japan
- Prior art keywords
- jcv
- pml
- subject
- variant
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims abstract description 285
- 238000001514 detection method Methods 0.000 title claims description 49
- 241000701460 JC polyomavirus Species 0.000 title description 539
- 230000027455 binding Effects 0.000 claims abstract description 166
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims abstract description 104
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims abstract description 99
- 238000003556 assay Methods 0.000 claims abstract description 91
- 238000002650 immunosuppressive therapy Methods 0.000 claims abstract description 12
- 239000000523 sample Substances 0.000 claims description 151
- 239000012472 biological sample Substances 0.000 claims description 135
- 238000011282 treatment Methods 0.000 claims description 132
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 68
- 108090000565 Capsid Proteins Proteins 0.000 claims description 65
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 64
- 210000002700 urine Anatomy 0.000 claims description 56
- 238000006467 substitution reaction Methods 0.000 claims description 50
- 230000001965 increasing effect Effects 0.000 claims description 40
- 238000004458 analytical method Methods 0.000 claims description 39
- 238000012217 deletion Methods 0.000 claims description 37
- 230000037430 deletion Effects 0.000 claims description 37
- 150000007523 nucleic acids Chemical group 0.000 claims description 33
- 238000002965 ELISA Methods 0.000 claims description 27
- 230000001506 immunosuppresive effect Effects 0.000 claims description 21
- 125000000539 amino acid group Chemical class 0.000 claims description 19
- 210000004369 blood Anatomy 0.000 claims description 18
- 239000008280 blood Substances 0.000 claims description 18
- 230000035945 sensitivity Effects 0.000 claims description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 9
- 230000004048 modification Effects 0.000 claims description 4
- 238000012986 modification Methods 0.000 claims description 4
- 230000035772 mutation Effects 0.000 abstract description 234
- 239000000203 mixture Substances 0.000 abstract description 25
- 230000002829 reductive effect Effects 0.000 abstract description 21
- 239000002955 immunomodulating agent Substances 0.000 abstract description 13
- 229940121354 immunomodulator Drugs 0.000 abstract description 13
- 230000004044 response Effects 0.000 abstract description 7
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 575
- 101710197658 Capsid protein VP1 Proteins 0.000 description 248
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 244
- 101710132601 Capsid protein Proteins 0.000 description 243
- 101710108545 Viral protein 1 Proteins 0.000 description 243
- 108090000765 processed proteins & peptides Proteins 0.000 description 164
- 102000004196 processed proteins & peptides Human genes 0.000 description 150
- 229920001184 polypeptide Polymers 0.000 description 144
- 241000700605 Viruses Species 0.000 description 143
- 230000003612 virological effect Effects 0.000 description 114
- 210000004027 cell Anatomy 0.000 description 108
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 92
- 208000015181 infectious disease Diseases 0.000 description 87
- 150000001413 amino acids Chemical class 0.000 description 76
- 210000002381 plasma Anatomy 0.000 description 55
- 108090000623 proteins and genes Proteins 0.000 description 47
- 239000003795 chemical substances by application Substances 0.000 description 44
- 235000018102 proteins Nutrition 0.000 description 41
- 102000004169 proteins and genes Human genes 0.000 description 40
- 108020004414 DNA Proteins 0.000 description 39
- 102000053602 DNA Human genes 0.000 description 39
- 239000003018 immunosuppressive agent Substances 0.000 description 39
- 239000003814 drug Substances 0.000 description 38
- 150000002270 gangliosides Chemical class 0.000 description 38
- 210000003169 central nervous system Anatomy 0.000 description 34
- 241001505332 Polyomavirus sp. Species 0.000 description 32
- 108020003175 receptors Proteins 0.000 description 30
- 102000005962 receptors Human genes 0.000 description 30
- 150000001875 compounds Chemical class 0.000 description 29
- 210000003743 erythrocyte Anatomy 0.000 description 29
- 230000035931 haemagglutination Effects 0.000 description 29
- 102000039446 nucleic acids Human genes 0.000 description 26
- 108020004707 nucleic acids Proteins 0.000 description 26
- 210000004556 brain Anatomy 0.000 description 25
- 239000000872 buffer Substances 0.000 description 25
- 210000003734 kidney Anatomy 0.000 description 24
- 108020004705 Codon Proteins 0.000 description 22
- 239000002245 particle Substances 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 208000024891 symptom Diseases 0.000 description 21
- 239000012634 fragment Substances 0.000 description 20
- 229940125721 immunosuppressive agent Drugs 0.000 description 20
- 210000001519 tissue Anatomy 0.000 description 20
- 229940124597 therapeutic agent Drugs 0.000 description 19
- 229960005486 vaccine Drugs 0.000 description 18
- 201000010099 disease Diseases 0.000 description 17
- 238000012544 monitoring process Methods 0.000 description 17
- 241000283973 Oryctolagus cuniculus Species 0.000 description 16
- 229940079593 drug Drugs 0.000 description 16
- 230000002519 immonomodulatory effect Effects 0.000 description 16
- 210000000987 immune system Anatomy 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 16
- 108020004459 Small interfering RNA Proteins 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 230000001225 therapeutic effect Effects 0.000 description 15
- 230000003321 amplification Effects 0.000 description 14
- 239000000427 antigen Substances 0.000 description 14
- 230000000875 corresponding effect Effects 0.000 description 14
- 210000004498 neuroglial cell Anatomy 0.000 description 14
- 238000003199 nucleic acid amplification method Methods 0.000 description 14
- 150000004044 tetrasaccharides Chemical class 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 230000008859 change Effects 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 230000003993 interaction Effects 0.000 description 12
- 210000004698 lymphocyte Anatomy 0.000 description 12
- 230000002093 peripheral effect Effects 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 230000001413 cellular effect Effects 0.000 description 11
- 229940124589 immunosuppressive drug Drugs 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 206010061598 Immunodeficiency Diseases 0.000 description 10
- 238000011161 development Methods 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000007935 neutral effect Effects 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 229940124598 therapeutic candidate Drugs 0.000 description 10
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 9
- 238000007476 Maximum Likelihood Methods 0.000 description 9
- 208000036142 Viral infection Diseases 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000013068 control sample Substances 0.000 description 9
- 238000003753 real-time PCR Methods 0.000 description 9
- 229920002477 rna polymer Polymers 0.000 description 9
- 230000009385 viral infection Effects 0.000 description 9
- 208000029462 Immunodeficiency disease Diseases 0.000 description 8
- 229960005475 antiinfective agent Drugs 0.000 description 8
- 239000004599 antimicrobial Substances 0.000 description 8
- 238000010367 cloning Methods 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 8
- 108010023958 glycyl-threonyl-alanyl-methionyl-arginyl-isoleucyl-leucyl-glycyl-glycyl-valyl-isoleucine Proteins 0.000 description 8
- 230000007813 immunodeficiency Effects 0.000 description 8
- 230000002584 immunomodulator Effects 0.000 description 8
- 229960003444 immunosuppressant agent Drugs 0.000 description 8
- 230000000813 microbial effect Effects 0.000 description 8
- 125000005629 sialic acid group Chemical group 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 238000003657 Likelihood-ratio test Methods 0.000 description 7
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 7
- 241000829388 Mus musculus polyomavirus 1 Species 0.000 description 7
- 102000005348 Neuraminidase Human genes 0.000 description 7
- 108010006232 Neuraminidase Proteins 0.000 description 7
- 210000001130 astrocyte Anatomy 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 7
- 230000001861 immunosuppressant effect Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 229960005027 natalizumab Drugs 0.000 description 7
- 210000004248 oligodendroglia Anatomy 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 230000029812 viral genome replication Effects 0.000 description 7
- 208000030507 AIDS Diseases 0.000 description 6
- 208000014912 Central Nervous System Infections Diseases 0.000 description 6
- 206010061818 Disease progression Diseases 0.000 description 6
- 101710121996 Hexon protein p72 Proteins 0.000 description 6
- 108090001090 Lectins Proteins 0.000 description 6
- 102000004856 Lectins Human genes 0.000 description 6
- 101710125418 Major capsid protein Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 101150024766 VP1 gene Proteins 0.000 description 6
- 230000002860 competitive effect Effects 0.000 description 6
- 230000005750 disease progression Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 239000002523 lectin Substances 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 230000008506 pathogenesis Effects 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241000282672 Ateles sp. Species 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 230000008499 blood brain barrier function Effects 0.000 description 5
- 210000001218 blood-brain barrier Anatomy 0.000 description 5
- 238000004422 calculation algorithm Methods 0.000 description 5
- 210000000234 capsid Anatomy 0.000 description 5
- 208000015114 central nervous system disease Diseases 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229920001542 oligosaccharide Polymers 0.000 description 5
- 150000002482 oligosaccharides Chemical class 0.000 description 5
- 238000013081 phylogenetic analysis Methods 0.000 description 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000009870 specific binding Effects 0.000 description 5
- 230000009897 systematic effect Effects 0.000 description 5
- 210000004926 tubular epithelial cell Anatomy 0.000 description 5
- 108091035707 Consensus sequence Proteins 0.000 description 4
- 238000012286 ELISA Assay Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 101150016155 Pml gene Proteins 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 230000003044 adaptive effect Effects 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 230000001351 cycling effect Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 206010022000 influenza Diseases 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- VELGMVLNORPMAO-JTFNWEOFSA-N n-[(e)-1-[(3r,4r,5s,6r)-5-[(2s,3r,4r,5r,6r)-5-[(2s,3r,4r,5r,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)-4-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxym Chemical compound O[C@@H]1[C@@H](O)C(OCC(NC(=O)CCCCCCCCCCCCCCCCC)C(O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 VELGMVLNORPMAO-JTFNWEOFSA-N 0.000 description 4
- 238000007857 nested PCR Methods 0.000 description 4
- 239000012454 non-polar solvent Substances 0.000 description 4
- 150000002894 organic compounds Chemical class 0.000 description 4
- 239000002798 polar solvent Substances 0.000 description 4
- 102000054765 polymorphisms of proteins Human genes 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 210000003296 saliva Anatomy 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 108091023037 Aptamer Proteins 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 208000016192 Demyelinating disease Diseases 0.000 description 3
- 206010064571 Gene mutation Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 208000031886 HIV Infections Diseases 0.000 description 3
- 102220558720 Hemogen_D66G_mutation Human genes 0.000 description 3
- 206010023163 JC virus infection Diseases 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 238000010222 PCR analysis Methods 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 208000024777 Prion disease Diseases 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 3
- 108070000030 Viral receptors Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000001064 anti-interferon Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 238000001493 electron microscopy Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000002751 lymph Anatomy 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 3
- 229960004866 mycophenolate mofetil Drugs 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 210000002741 palatine tonsil Anatomy 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000007918 pathogenicity Effects 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 229920000128 polypyrrole Polymers 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000008707 rearrangement Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 102200118256 rs33969400 Human genes 0.000 description 3
- 102220041466 rs483353023 Human genes 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 210000001138 tear Anatomy 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 208000031504 Asymptomatic Infections Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 206010014612 Encephalitis viral Diseases 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 241000712431 Influenza A virus Species 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- SQVRNKJHWKZAKO-LUWBGTNYSA-N N-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-LUWBGTNYSA-N 0.000 description 2
- 208000033952 Paralysis flaccid Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 240000006028 Sambucus nigra Species 0.000 description 2
- 235000003142 Sambucus nigra Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 206010054094 Tumour necrosis Diseases 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 206010058874 Viraemia Diseases 0.000 description 2
- 108010066342 Virus Receptors Proteins 0.000 description 2
- 102000018265 Virus Receptors Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- NWMHDZMRVUOQGL-CZEIJOLGSA-N almurtide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)CO[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O NWMHDZMRVUOQGL-CZEIJOLGSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000010256 biochemical assay Methods 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- 239000000430 cytokine receptor antagonist Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 235000008995 european elder Nutrition 0.000 description 2
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 208000028331 flaccid paralysis Diseases 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 238000012252 genetic analysis Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 210000001985 kidney epithelial cell Anatomy 0.000 description 2
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004880 lymph fluid Anatomy 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000000302 molecular modelling Methods 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 208000037821 progressive disease Diseases 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 102220233398 rs745611450 Human genes 0.000 description 2
- 238000003118 sandwich ELISA Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000012916 structural analysis Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
- 238000011285 therapeutic regimen Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 201000002498 viral encephalitis Diseases 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- CERZMXAJYMMUDR-QBTAGHCHSA-N 5-amino-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosonic acid Chemical compound N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO CERZMXAJYMMUDR-QBTAGHCHSA-N 0.000 description 1
- 208000000230 African Trypanosomiasis Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 208000006740 Aseptic Meningitis Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 108010084313 CD58 Antigens Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 101800000594 Capsid protein 1 Proteins 0.000 description 1
- 101710197665 Capsid protein VP2 Proteins 0.000 description 1
- 101800001319 Capsid protein VP3 Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108010039939 Cell Wall Skeleton Proteins 0.000 description 1
- 206010051290 Central nervous system lesion Diseases 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 206010053172 Fatal outcomes Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 208000034800 Leukoencephalopathies Diseases 0.000 description 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
- 206010024641 Listeriosis Diseases 0.000 description 1
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000010315 Mastoiditis Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027201 Meningitis aseptic Diseases 0.000 description 1
- 206010027250 Meningitis mumps Diseases 0.000 description 1
- 206010027260 Meningitis viral Diseases 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 241000702321 Microvirus Species 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028400 Mutagenic effect Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- 108700015872 N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine Proteins 0.000 description 1
- 108700020354 N-acetylmuramyl-threonyl-isoglutamine Proteins 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 108010046016 Peanut Agglutinin Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 208000001676 Polyomavirus Infections Diseases 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 102220635535 Vacuolar protein sorting-associated protein 33A_D66H_mutation Human genes 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 208000005181 Varicella Zoster Virus Infection Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 108010076089 accutase Proteins 0.000 description 1
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- PGUYIHLFQOCHKH-FLPQJDCLSA-N alpha-N-acetylneuraminosyl-(2->3)-[beta-D-galactosyl-(1->3)-N-acetyl-beta-D-galactosaminyl-(1->4)]-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-N-acetylsphingosine Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC(C)=O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 PGUYIHLFQOCHKH-FLPQJDCLSA-N 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000781 anti-lymphocytic effect Effects 0.000 description 1
- 230000002072 anti-mutant effect Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000004520 cell wall skeleton Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- ODZUPGUSIOTTSS-UHFFFAOYSA-N cytosporin A Natural products O=C1C(CCCCC)=C(C=O)C2OC(C)(C)C(O)CC22C1O2 ODZUPGUSIOTTSS-UHFFFAOYSA-N 0.000 description 1
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
- 229960000766 danazol Drugs 0.000 description 1
- 229960000860 dapsone Drugs 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-M deoxycholate Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-M 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003166 dihydrofolate reductase inhibitor Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 150000002339 glycosphingolipids Chemical class 0.000 description 1
- 229960002706 gusperimus Drugs 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 208000029080 human African trypanosomiasis Diseases 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000022760 infectious otitis media Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 1
- 229960005225 mifamurtide Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 231100000243 mutagenic effect Toxicity 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- IDINUJSAMVOPCM-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-INIZCTEOSA-N 0.000 description 1
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 229940023146 nucleic acid vaccine Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 208000037955 postinfectious encephalomyelitis Diseases 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000003498 protein array Methods 0.000 description 1
- 208000028172 protozoa infectious disease Diseases 0.000 description 1
- 239000000649 purine antagonist Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000011155 quantitative monitoring Methods 0.000 description 1
- 238000013139 quantization Methods 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102220197921 rs121913458 Human genes 0.000 description 1
- 102220005155 rs34621955 Human genes 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 108010061514 sialic acid receptor Proteins 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 201000002612 sleeping sickness Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 201000002311 trypanosomiasis Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940079023 tysabri Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 208000010531 varicella zoster infection Diseases 0.000 description 1
- 230000007501 viral attachment Effects 0.000 description 1
- 201000010044 viral meningitis Diseases 0.000 description 1
- 230000009447 viral pathogenesis Effects 0.000 description 1
- 230000007485 viral shedding Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15031009P | 2009-02-05 | 2009-02-05 | |
| US61/150,310 | 2009-02-05 | ||
| PCT/US2010/000342 WO2010090757A1 (en) | 2009-02-05 | 2010-02-05 | Methods for the detection of jc polyoma virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012517017A true JP2012517017A (ja) | 2012-07-26 |
| JP2012517017A5 JP2012517017A5 (enExample) | 2013-03-14 |
Family
ID=42542341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011549163A Ceased JP2012517017A (ja) | 2009-02-05 | 2010-02-05 | Ｊｃポリオーマウイルスの検出のための方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20130101985A9 (enExample) |
| EP (1) | EP2394163B1 (enExample) |
| JP (1) | JP2012517017A (enExample) |
| CN (2) | CN104316696A (enExample) |
| AU (1) | AU2010210979B2 (enExample) |
| BR (1) | BRPI1016273A2 (enExample) |
| CA (1) | CA2751364C (enExample) |
| ES (1) | ES2842425T3 (enExample) |
| NZ (1) | NZ594973A (enExample) |
| SG (2) | SG173201A1 (enExample) |
| WO (1) | WO2010090757A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016513072A (ja) * | 2012-12-31 | 2016-05-12 | ニューリミューン ホールディング エイジー | ポリオーマウイルス関連疾患の治療および防止のための組換えヒト抗体 |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1988921A4 (en) | 2006-02-28 | 2010-02-10 | Elan Pharm Inc | METHOD FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB |
| EP3360900A1 (en) | 2006-03-03 | 2018-08-15 | Biogen MA Inc. | Methods of treating inflammatory and autoimmune diseases with natalizumab |
| JP2012517017A (ja) | 2009-02-05 | 2012-07-26 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Ｊｃポリオーマウイルスの検出のための方法 |
| US11287423B2 (en) | 2010-01-11 | 2022-03-29 | Biogen Ma Inc. | Assay for JC virus antibodies |
| AU2011203815B2 (en) | 2010-01-11 | 2015-11-26 | Biogen Ma Inc. | Assay for JC virus antibodies |
| WO2012166971A2 (en) | 2011-05-31 | 2012-12-06 | Biogen Idec Ma Inc. | Method of assessing risk of pml |
| LT2734544T (lt) | 2011-07-18 | 2021-04-26 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Su poliomavirusu susijusios patologijos slopinimo metodai ir kompozicijos |
| EP2548567A1 (en) | 2011-07-22 | 2013-01-23 | Universitätsklinikum Hamburg-Eppendorf | Polyoma virus JC peptides and proteins in vaccination and diagnostic applications |
| EP2636746A1 (en) | 2012-03-06 | 2013-09-11 | Life Science Inkubator | A novel drug delivery system based on JCV-VLP |
| DK2828292T3 (da) | 2012-03-20 | 2019-01-02 | Biogen Ma Inc | Jcv-neutraliserende antistoffer |
| PT2828284T (pt) | 2012-03-20 | 2019-06-17 | Biogen Ma Inc | Jcv neutralizando anticorpos |
| WO2013192100A1 (en) | 2012-06-18 | 2013-12-27 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods and compositions for detecting jc virus |
| EP2774991B1 (en) * | 2013-03-06 | 2017-12-06 | Life Science Inkubator Betriebs GmbH & Co. KG | Drug delivery system for use in the treatment or diagnosis of neurological disorders |
| WO2014145243A2 (en) * | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | High resolution melting analysis assay for the detection of viral dna |
| EP3004334A4 (en) | 2013-05-28 | 2016-12-21 | Biogen Ma Inc | METHOD FOR ASSESSING A PML RISK |
| US9931393B2 (en) | 2013-12-20 | 2018-04-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunogenic JC polyomavirus compositions and methods of use |
| US20200197544A1 (en) * | 2017-04-26 | 2020-06-25 | Biogen Ma Inc. | Jcv imaging methods and compositions |
| CN112442553A (zh) * | 2020-10-27 | 2021-03-05 | 深圳市罗湖区人民医院 | 一种用于JCPyV检测与分型的试剂盒及方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0967397A (ja) * | 1995-06-23 | 1997-03-11 | Eisai Co Ltd | 抗ｊｃウイルス抗体 |
| JP2003061693A (ja) * | 2001-06-28 | 2003-03-04 | Jenapharm Gmbh & Co Kg | ウイルス様粒子、その製造方法およびその使用 |
| JP2007197441A (ja) * | 1995-11-22 | 2007-08-09 | Schering Ag | ウイルス様粒子、その製造方法、その使用、それを含有する調剤学的組成物、ｊｃｖに対する特異的抗体を免疫学的に測定する方法及び試験キット |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000506378A (ja) | 1996-01-26 | 2000-05-30 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア． | アナライトの直接的発色検出用のポリマーフィルム、アッセイおよび方法 |
| JP4840792B2 (ja) | 2001-11-22 | 2011-12-21 | 独立行政法人科学技術振興機構 | ＪＣウイルスａｇｎｏを対象としたＰＭＬの治療 |
| US20080131928A1 (en) | 2004-07-01 | 2008-06-05 | Hiroshi Handa | Viral Particle-Like Construct and Method of Forming the Same Under Physiological Conditions |
| JP4757103B2 (ja) | 2005-06-13 | 2011-08-24 | 学校法人関西文理総合学園 | 試料中のウイルスを検出する方法およびシステム |
| US7468186B2 (en) | 2005-07-22 | 2008-12-23 | City Of Hope | Polyomavirus cellular epitopes and uses therefor |
| EP1951888B1 (en) | 2005-11-09 | 2012-09-05 | PrimeraDx, Inc. | Multiplexed quantitative detection of pathogens |
| US7769230B2 (en) * | 2006-11-30 | 2010-08-03 | Eastman Kodak Company | Producing low resolution images |
| WO2008077511A1 (en) | 2006-12-22 | 2008-07-03 | Karolinska Institutet Innovations Ab | Human polyomavirus and methods of diagnosis and treatment |
| JP2008249433A (ja) | 2007-03-29 | 2008-10-16 | Kansai Bunri Sogo Gakuen | 被験物質に対するプローブの結合親和性を測定する方法及びその利用 |
| WO2009100351A2 (en) | 2008-02-08 | 2009-08-13 | Alnylam Pharmaceuticals, Inc. | Delivery of rnai constructs to oligodendrocytes |
| JP2012517017A (ja) | 2009-02-05 | 2012-07-26 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Ｊｃポリオーマウイルスの検出のための方法 |
| BR112014002126A2 (pt) | 2011-07-29 | 2017-02-21 | Biogen Idec Inc | ensaio para detecção de dna do vírus jc |
| AR095089A1 (es) | 2013-01-30 | 2015-09-30 | Biogen Idec Inc | Ensayo de detección de adn de virus jc |
-
2010
- 2010-02-05 JP JP2011549163A patent/JP2012517017A/ja not_active Ceased
- 2010-02-05 ES ES10738871T patent/ES2842425T3/es active Active
- 2010-02-05 CN CN201410478514.8A patent/CN104316696A/zh active Pending
- 2010-02-05 EP EP10738871.2A patent/EP2394163B1/en active Active
- 2010-02-05 BR BRPI1016273-9A patent/BRPI1016273A2/pt not_active Application Discontinuation
- 2010-02-05 SG SG2011055514A patent/SG173201A1/en unknown
- 2010-02-05 CA CA2751364A patent/CA2751364C/en active Active
- 2010-02-05 SG SG2014009120A patent/SG2014009120A/en unknown
- 2010-02-05 US US13/147,484 patent/US20130101985A9/en not_active Abandoned
- 2010-02-05 WO PCT/US2010/000342 patent/WO2010090757A1/en not_active Ceased
- 2010-02-05 CN CN201080014394.6A patent/CN102369436B/zh active Active
- 2010-02-05 AU AU2010210979A patent/AU2010210979B2/en active Active
- 2010-02-05 NZ NZ594973A patent/NZ594973A/xx unknown
-
2015
- 2015-01-22 US US14/603,002 patent/US9696307B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0967397A (ja) * | 1995-06-23 | 1997-03-11 | Eisai Co Ltd | 抗ｊｃウイルス抗体 |
| JP2007197441A (ja) * | 1995-11-22 | 2007-08-09 | Schering Ag | ウイルス様粒子、その製造方法、その使用、それを含有する調剤学的組成物、ｊｃｖに対する特異的抗体を免疫学的に測定する方法及び試験キット |
| JP2003061693A (ja) * | 2001-06-28 | 2003-03-04 | Jenapharm Gmbh & Co Kg | ウイルス様粒子、その製造方法およびその使用 |
Non-Patent Citations (1)
| Title |
|---|
| JPN6016020147; Ｚｈｅｎｇ ＨＹ、外９名: 'Ｃｈａｒａｃｔｅｒｉｚａｔｉｏｎ ｏｆ ｔｈｅ ＶＰ１ ｌｏｏｐ ｍｕｔａｔｉｏｎｓ ｗｉｄｅｓｐｒｅａｄ ａｍｏｎｇ ＪＣ ｐｏｌｙｏｍａｖｉｒｕｓ ｉｓｏｌａｔｅｓ ａｓｓｏｃｉａｔｅｄ ｗｉｔｈ' Ｂｉｏｃｈｅｍ Ｂｉｏｐｈｙｓ Ｒｅｓ Ｃｏｍｍｕｎ． Ｖｏｌ．３３３，Ｎｏ．３, 200508, Ｐａｇｅ．９９６-１００２ * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016513072A (ja) * | 2012-12-31 | 2016-05-12 | ニューリミューン ホールディング エイジー | ポリオーマウイルス関連疾患の治療および防止のための組換えヒト抗体 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102369436B (zh) | 2014-10-22 |
| EP2394163A4 (en) | 2012-08-01 |
| AU2010210979B2 (en) | 2015-12-10 |
| SG173201A1 (en) | 2011-08-29 |
| US20130101985A9 (en) | 2013-04-25 |
| EP2394163B1 (en) | 2020-08-19 |
| BRPI1016273A2 (pt) | 2020-12-01 |
| CA2751364A1 (en) | 2010-08-12 |
| SG2014009120A (en) | 2014-03-28 |
| NZ594973A (en) | 2012-05-25 |
| US9696307B2 (en) | 2017-07-04 |
| US20150219651A1 (en) | 2015-08-06 |
| WO2010090757A1 (en) | 2010-08-12 |
| ES2842425T3 (es) | 2021-07-14 |
| AU2010210979A1 (en) | 2011-09-22 |
| CA2751364C (en) | 2017-06-20 |
| CN102369436A (zh) | 2012-03-07 |
| CN104316696A (zh) | 2015-01-28 |
| US20120258443A1 (en) | 2012-10-11 |
| EP2394163A1 (en) | 2011-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9696307B2 (en) | Methods for the detection of JC polyoma virus | |
| Flyak et al. | Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2–MPER region | |
| Ladner | Mapping the epitopes of antibodies | |
| ES2673230T3 (es) | Anticuerpo monoclonal humano contra la proteína VP1 del virus JC | |
| JP6735005B2 (ja) | グリピカンエピトープおよびその使用 | |
| Shang et al. | NRP1 is a receptor for mammalian orthoreovirus engaged by distinct capsid subunits | |
| WO2021209824A1 (en) | Methods and products for serological analysis of sars-cov-2 infection | |
| CN110914685A (zh) | Rep蛋白作为蛋白质抗原用于诊断试验 | |
| JP5755239B2 (ja) | Ｈ−１パルボウイルスに結合する抗体 | |
| Byrnes et al. | A SARS-CoV-2 serological assay to determine the presence of blocking antibodies that compete for human ACE2 binding | |
| Ssebyatika et al. | Broadly neutralizing antibodies isolated from HEV convalescents confer protective effects in human liver-chimeric mice | |
| US20190107544A1 (en) | Bk virus serology assessment of progressive multifocal leukoencephalopathy (pml) risk | |
| Kallunki et al. | Rational selection of the monoclonal α-synuclein antibody amlenetug (Lu AF82422) for the treatment of α-synucleinopathies | |
| Li et al. | A monoclonal antibody targeting conserved regions of pre-fusion protein cross-neutralizes Nipah and Hendra virus variants | |
| Wang et al. | A subset of Memory B-derived antibody repertoire from 3-dose vaccinees is ultrapotent against diverse and highly transmissible SARS-CoV-2 variants, including Omicron | |
| Wang et al. | Molecular blueprints of the Langya virus attachment and fusion glycoproteins | |
| US20240402174A1 (en) | Methods for determining norovirus-reactive antibodies | |
| US20240116994A1 (en) | Peptides And Use Thereof For Diagnosing And Treating Antiphospholipid Syndrome | |
| JP2024051908A (ja) | コロナウイルス中和抗体 | |
| TWI249407B (en) | Hybridoma cell line for producing monoclonal antibody against porcine endogenous retrovirus envelope protein and the produced monoclonal antibody and their use | |
| KR20240009996A (ko) | 항노로바이러스 항체 | |
| KR20240009995A (ko) | 항노로바이러스 항체 | |
| Bywaters | Anti-Capsid Monoclonal Antibodies: Tools to Assess HPV Neutralization and Capsid Structure | |
| Acton | Immunoglobulins—Advances in Research and Application: 2013 Edition | |
| Zhou et al. | A protective broadly cross-reactive human antibody defines a conserved |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130117 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130117 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20131030 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131101 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140131 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140207 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140228 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140307 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140325 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140401 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140428 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141023 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150121 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150414 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150930 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160201 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20160318 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160601 |
|
| A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20161020 |